Pneumococcal

Low pneumococcal vaccine rates have potential to significantly impact a variety of at-risk populations, even groups of certain health care workers.

New research shows older adults vaccinate more when confident navigating their health care.

Meta-analysis shows PCV13 followed by PPSV23 boosts pneumococcal immunity in seniors without added adverse effects.

Social determinants of health shape pneumococcal risk, making vaccination especially important for specific populations.

In response to evolving serotypes and vaccine guidance, researchers assess the most effective pneumococcal vaccination strategies across Taiwan.

Researchers aim to update and expand on register-based surveillance of severe acute respiratory infections related to Streptococcus pneumoniae in Denmark.

Investigators of the multicenter cohort aim to determine if the 13-valent pneumococcal conjugate vaccine impacted disease activity over a 24-month period.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

Serotype 19F resurges despite PCVs, raising invasive disease risk in older adults; pharmacists track immune evasion, variants, and boost adherence.

With the OPUS-1, 2, and 3 trials underway, Vax-31 has the potential to become the first pneumococcal vaccine of its kind, demonstrating never-before-seen impacts on disease burden.

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

The top pneumococcal stories of 2025 explored the evolving landscape of pneumococcal vaccination.

With little evidence on vaccine coverage for people living with HIV, researchers explored pneumococcal vaccine rates between 2014 and 2023.

With constant vaccine and guideline updates reserved for pneumococcal diseases, pharmacists continue to be the authority on pneumococcal vaccine administration.

In part 3 of our interview with Megan Smith, PharmD, she discusses the common reasons for hesitancy among patients, specifically for the pneumococcal vaccine.

Megan Smith, PharmD, discusses how pharmacists have taken reigns in boosting pneumococcal vaccine rates across health care.

Megan Smith, PharmD, breaks down the public health sector’s current understanding and approach toward pneumococcal vaccines.

Exploring the real-time capabilities of chatbots and artificial intelligence (AI), researchers investigate how this technology would impact older adults’ pneumococcal vaccine rates.

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

Researchers conduct a cost-effectiveness analysis to uncover the public health and economic impacts of PCV20 among Australian children.